MX336427B - Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas. - Google Patents

Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas.

Info

Publication number
MX336427B
MX336427B MX2013012241A MX2013012241A MX336427B MX 336427 B MX336427 B MX 336427B MX 2013012241 A MX2013012241 A MX 2013012241A MX 2013012241 A MX2013012241 A MX 2013012241A MX 336427 B MX336427 B MX 336427B
Authority
MX
Mexico
Prior art keywords
treatment
positive bacteria
detection
gram positive
streptococcus
Prior art date
Application number
MX2013012241A
Other languages
English (en)
Other versions
MX2013012241A (es
Inventor
Vincent A Fischetti
Jonathan Schmitz
Daniel Gilmer
Chad Euler
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of MX2013012241A publication Critical patent/MX2013012241A/es
Publication of MX336427B publication Critical patent/MX336427B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos, composiciones y artículos de fabricación útiles para la mejora y tratamiento profiláctico y terapéutico de bacterias gram-positivas, incluyendo Streptococcus y Staphylococcus, y condiciones relacionadas; la invención provee composiciones y métodos que incorporan y utilizan usinas bacteriófagas derivadas de Streptococcus suis, particularmente enzimas líticas PlySs2 y/o PlySs1 y variantes de las mismas, incluyendo sus truncamientos; se proveen métodos para el tratamiento de humanos. Una composición farmacéutica para destruir bacterias gram positivas, la composición caracterizada porque comprende el polipéptido de lisina aislado que comprende la secuencia de aminoácidos de SEQ ID NO:3, o variantes del mismo que tienen por lo menos 80% de identidad con el polipéptido de SEQ ID NO: 3, y es eficaz para destruir bacterias gram positivas.
MX2013012241A 2011-04-21 2012-04-20 Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas. MX336427B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477836P 2011-04-21 2011-04-21
PCT/US2012/034456 WO2012145630A2 (en) 2011-04-21 2012-04-20 Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria

Publications (2)

Publication Number Publication Date
MX2013012241A MX2013012241A (es) 2014-05-07
MX336427B true MX336427B (es) 2016-01-18

Family

ID=47042182

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016000588A MX370442B (es) 2011-04-21 2012-04-20 Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
MX2013012241A MX336427B (es) 2011-04-21 2012-04-20 Lisinas de bacteriofago de estreptococcus para la deteccion y tratamiento de bacterias gram positivas.
MX2021007008A MX2021007008A (es) 2011-04-21 2013-10-18 Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016000588A MX370442B (es) 2011-04-21 2012-04-20 Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007008A MX2021007008A (es) 2011-04-21 2013-10-18 Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.

Country Status (12)

Country Link
US (7) US9034322B2 (es)
EP (2) EP2699253B1 (es)
JP (4) JP6139509B2 (es)
CN (4) CN107189997A (es)
AU (3) AU2012245357B2 (es)
CA (1) CA2833409A1 (es)
DK (1) DK2699253T3 (es)
ES (1) ES2682670T3 (es)
HK (2) HK1244503A1 (es)
IL (4) IL228869B (es)
MX (3) MX370442B (es)
WO (1) WO2012145630A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
WO2012145573A2 (en) * 2011-04-21 2012-10-26 Universiteit Utrecht Holding Bv Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
NL2007038C2 (en) * 2011-07-04 2013-01-07 Vereniging Voor Christelijk Hoger Onderwijs System and method for predicting the viability of a body tissue in a patient, and measuring device used therein.
CN111803620A (zh) * 2012-05-09 2020-10-23 康特拉费克特公司 使用噬菌体溶素的生物膜预防、破坏和处理
KR20210121313A (ko) * 2012-05-09 2021-10-07 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
CN106659748B (zh) 2014-06-26 2021-08-31 洛克菲勒大学 不动杆菌属溶素
CN104726439B (zh) * 2015-04-13 2017-11-14 武汉菲吉乐科生物科技有限公司 一种广谱的链球菌裂解酶及其应用
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
WO2017023680A1 (en) * 2015-07-31 2017-02-09 The Regents Of The University Of California Mycobacterium lysterase: a novel treatment for acne
WO2017044989A1 (en) * 2015-09-13 2017-03-16 The Rockefeller University Clostridium difficile BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF Clostridium difficile BACTERIA INFECTION
CN108348574B (zh) 2015-09-17 2022-11-01 抗非特公司 具有对抗革兰氏阴性菌的活性的溶素多肽
MX2018013372A (es) 2016-05-12 2019-05-09 Contrafect Corp Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos.
CA3069679A1 (en) * 2017-07-10 2019-01-17 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
JP2021509582A (ja) * 2018-01-05 2021-04-01 アジトラ インコーポレーテッド ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）属細菌の栄養要求株
EP3758738A4 (en) * 2018-02-26 2021-12-08 Contrafect Corporation MODIFIED PLYSS2-LYSINE AND USES THEREOF
KR102073086B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-1 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073088B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-2 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073094B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-3 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
EP3837348A4 (en) * 2018-08-17 2022-07-27 Becton, Dickinson and Company TESTING FOR ANTIBIOTIC SENSITIVITY USING MICRODROPLET
EP3864166A1 (en) 2018-10-12 2021-08-18 Quidel Corporation Extraction reagent for use in an assay for detection of group a streptococcus
CN114025782A (zh) * 2019-03-22 2022-02-08 康特拉费克特公司 治疗感染性心内膜炎的方法
JP2022526978A (ja) * 2019-04-05 2022-05-27 コントラフェクト コーポレイション ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体
EP3980049A4 (en) * 2019-04-11 2023-07-19 Contrafect Corporation METHOD OF TREATMENT AND PREVENTION OF BONE AND JOINT INFECTIONS
CA3178761A1 (en) * 2020-05-19 2021-11-25 Raymond Schuch Modified plyss2 lysins and antibiotic combinations for use against gram-positive bacteria
US20220087266A1 (en) * 2020-09-22 2022-03-24 Mars, Incorporated Compositions and methods for controlling mycotoxin production
CN114480299B (zh) * 2020-10-27 2023-08-29 暨南大学 一种蜡样芽胞杆菌噬菌体及其应用
CN112760312B (zh) * 2021-01-20 2022-06-17 华中农业大学 一种裂解革兰氏阳性菌的裂解酶plyssX609及其应用
WO2023049747A1 (en) * 2021-09-22 2023-03-30 Elanco Us Inc. Streptococcus suis lytic enzyme compositions and methods of use thereof
KR20240015755A (ko) * 2022-07-26 2024-02-06 주식회사 인트론바이오테크놀로지 연쇄상구균에 대하여 용균 활성을 갖는 항균단백질
WO2024059184A1 (en) * 2022-09-16 2024-03-21 The Johns Hopkins University Machine learning systems and related aspects for the detection of disease states
CN116640754B (zh) * 2023-07-21 2023-10-10 临沂大学 一种链球菌前噬菌体裂解酶lys224及应用
CN117051043B (zh) * 2023-10-11 2024-01-30 圆因(北京)生物科技有限公司 一种基于环状rna编码耐甲氧西林金黄色葡萄球菌内溶素及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278378A (en) 1962-04-19 1966-10-11 Schindler Charles Alvin Staphylococcus-derived antibiotic
US3398056A (en) 1964-07-10 1968-08-20 Mead Johnson & Co Process for producing lysostaphin by fermentation
US3594284A (en) 1968-06-04 1971-07-20 Mead Johnson & Co Lysostaphin fermentation with accelerated time cycle
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3486448T2 (de) 1983-11-14 1997-10-09 Columbia Lab Inc Bioadhäsive Mittel
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
EP0285649A4 (en) 1986-10-08 1990-06-27 David Bernstein METHOD FOR EXPOSING ANTIGENS OF GROUP A STREPTOCOCCUS AND IMPROVED DIAGNOSTIC TEST FOR THE IDENTIFICATION OF GROUP A STREPTOCOCCUS
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US6017528A (en) 1997-10-31 2000-01-25 New Horizons Diagnostics Therapeutic treatment of group A streptococcal infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
CN1352567A (zh) * 1999-02-25 2002-06-05 新眼界诊断公司 预防性和治疗性治疗链球菌感染的方法
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
WO2004027020A2 (en) 2002-05-17 2004-04-01 New Horizons Diagnostics Corporation Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
US8326388B2 (en) 2002-10-31 2012-12-04 Toshiba Medical Systems Corporation Method and apparatus for non-invasive measurement of living body characteristics by photoacoustics
US7217791B2 (en) * 2002-11-07 2007-05-15 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
WO2004104213A2 (en) * 2003-05-15 2004-12-02 The Rockefeller University Nucleic acids and polypeptides of c1 bacteriophage and uses thereof
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
WO2005089527A2 (en) 2004-03-24 2005-09-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of bacillus anthracis bacteria and spores
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
WO2007024628A2 (en) * 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
IE20060488A1 (en) * 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent
DE102006061002A1 (de) * 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
EP2225263A1 (en) 2007-11-26 2010-09-08 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
EP3263588A1 (en) 2008-07-03 2018-01-03 The Rockefeller University Isolated staphylococcus-specific soluble binding molecule
US8481289B2 (en) * 2008-07-24 2013-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Triple acting antimicrobials that are refractory to resistance development
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
KR101016918B1 (ko) * 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
US8951532B2 (en) * 2010-01-25 2015-02-10 Alere Scarborough, Inc. A25 bacteriophage lysin
WO2012145573A2 (en) * 2011-04-21 2012-10-26 Universiteit Utrecht Holding Bv Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock

Also Published As

Publication number Publication date
US20200002694A1 (en) 2020-01-02
IL271300A (en) 2020-01-30
US20230167427A9 (en) 2023-06-01
EP3252155A1 (en) 2017-12-06
JP6735796B2 (ja) 2020-08-05
JP6139509B2 (ja) 2017-05-31
EP2699253A2 (en) 2014-02-26
ES2682670T3 (es) 2018-09-21
AU2019204660A1 (en) 2019-07-18
NZ731111A (en) 2019-06-28
JP6284976B2 (ja) 2018-02-28
JP2014518849A (ja) 2014-08-07
US20200149025A1 (en) 2020-05-14
US20220064615A1 (en) 2022-03-03
JP6587655B2 (ja) 2019-10-09
IL271300B (en) 2021-12-01
JP2019022504A (ja) 2019-02-14
IL228869B (en) 2019-05-30
US20140072549A1 (en) 2014-03-13
AU2017202728B2 (en) 2019-04-04
WO2012145630A3 (en) 2014-05-01
AU2012245357A1 (en) 2013-11-14
US11111484B2 (en) 2021-09-07
MX370442B (es) 2019-12-13
US9034322B2 (en) 2015-05-19
HK1244503A1 (zh) 2018-08-10
US9914915B2 (en) 2018-03-13
US10544407B2 (en) 2020-01-28
DK2699253T3 (en) 2018-07-16
CN108578685A (zh) 2018-09-28
US20220127590A1 (en) 2022-04-28
CA2833409A1 (en) 2012-10-26
US20170298334A1 (en) 2017-10-19
IL266476B (en) 2020-01-30
US20150267185A1 (en) 2015-09-24
IL287530A (en) 2021-12-01
JP2016147903A (ja) 2016-08-18
AU2017202728A1 (en) 2017-05-18
US11155799B2 (en) 2021-10-26
HK1247956A1 (zh) 2018-10-05
CN107189997A (zh) 2017-09-22
AU2012245357B2 (en) 2017-06-08
JP2017171686A (ja) 2017-09-28
CN115887627A (zh) 2023-04-04
MX2013012241A (es) 2014-05-07
NZ616945A (en) 2015-11-27
WO2012145630A2 (en) 2012-10-26
EP2699253B1 (en) 2018-03-28
EP2699253A4 (en) 2015-07-01
CN103857410A (zh) 2014-06-11
AU2019204660B2 (en) 2021-01-28
IL266476A (en) 2019-06-30
IL228869A0 (en) 2013-12-31
NZ713076A (en) 2017-05-26
MX2021007008A (es) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2021007008A (es) Lisinas de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
IL274832A (en) Combinations of bacteriophage lysine and antibiotics against gram-positive bacteria
WO2013122888A3 (en) Methods of treating bacterial infections
BR112012033212A2 (pt) uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
WO2013184755A3 (en) Seca inhibitors and methods of making and using thereof
HK1207002A1 (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
GB201013307D0 (en) Anti-microbial metal organic framework
MX2013006873A (es) Una composicion que comprende un agente antibiotico y un agente dispersante o un agente antiadhesivo.
PH12014502680A1 (en) Polysaccharide compositions and methods of use
HRP20170987T1 (hr) Fibrinolitički pripravci koji sadrže bromelain i natokinazu za sprječavanje i liječenje flebotrombotičkih stanja
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
AU2012335397A8 (en) Novel bacteriophages
WO2012141540A3 (ko) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
WO2013155320A3 (en) Use of microbial gene products to prevent or treat microbial infections
WO2015063608A3 (en) Prevention and dispersion of biolfilm
PL391552A1 (pl) Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych rodzaju Stenotrophomonas
PL392681A1 (pl) Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych z rodzaju Klebsiella
IN2014KN02584A (es)
MX2013012603A (es) Vancomicina liposomal para el tratamiento de infecciones por estafilococo aureus resistente a la meticilina (sarm).
MY171941A (en) Pharmaceutical compositions